Alkem Laboratories: Pl find enclosed unaudited financial results along with Limited Review Report of the Company for quarter and…
Alkem Laboratories (ALKEM) filed a disclosure titled "Pl find enclosed unaudited financial results along with Limited Review Report of the Company for quarter and half year ended 30th Sept, 2026". The company is valued at about ₹63,047 crore.
What happened
Alkem Laboratories (ALKEM) filed a disclosure with the exchanges on 12 November 2026 at 01:55 PM titled "Pl find enclosed unaudited financial results along with Limited Review Report of the Company for quarter and half year ended 30th Sept, 2026".
Company snapshot
Alkem Laboratories is a mid-cap company in the Healthcare sector, with a market value of about ₹63,047 crore.
The stock last traded at ₹5,273, against a 52-week range of ₹4,811–₹5,933.5 (11.1% below the high).
Before this filing the shares had moved +2.3% over the month and −2.3% over three months. Average daily turnover over the last 20 sessions was about ₹50.7 crore.
Promoters held 49.70% at the end of Q1 FY27, down 1.50% points from the previous quarter. Foreign institutions owned 10.42% and domestic institutions 22.63%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,371 | 664.3 | 55.56 |
| Q2 FY26 | 4,001 | 765.1 | 63.99 |
| Q3 FY26 | 3,737 | 636 | 53.19 |
| Q4 FY26 | 3,603 | 236.5 | 19.77 |
| Q1 FY27 | 3,740 | 520 | 43.49 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +2.6% over five days; 58% of them rose the next day.
Market-wide, 11,631 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 12 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Alkem names former Zydus executive Dr Amrut Naik new CEO
- ALKEM Outlook for the Week
- Earnings To Watch: Alkem Laboratories Ltd (NSE:ALKEM) Q2 2027 -- GF Value Sees 32% Upside
- Bipin Lokegaonkar Joins Alkem Laboratories as Chief Information Security Officer
- Tech Query: Alkem Laboratories, Intellect Design Arena, Trent, SRF — What is the outlook? Where are these stocks headed?
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.